Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Elecoglipron

INVESTIGATIONAL

Oral non-peptide GLP-1 receptor agonist

1
graded results
0
ongoing records
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Elecoglipron is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Oral tablet; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Elecoglipron INVESTIGATIONAL
weight-loss Decrease
Very low evidence

Oral non-peptide GLP-1RA (ECC5004/AZD5004; INN elecoglipron), discovered by Eccogene, licensed to AstraZeneca. US phase 1 reported clinically meaningful weight...

Eccogene/AstraZeneca press (license Nov 2023; phase 1b topline Feb 2026) Source
Full findingOral non-peptide GLP-1RA (ECC5004/AZD5004; INN elecoglipron), discovered by Eccogene, licensed to AstraZeneca. US phase 1 reported clinically meaningful weight reductions regardless of T2D status plus glycaemic improvements in T2D. Eccogene reported positive topline phase 1b (China, Feb 2026). Advanced to phase 2b: VISTA (obesity), SOLSTICE (T2D).
PopulationPhase 1 (US) and phase 1b (China) in adults with obesity/overweight +/- T2D; phase 2b VISTA/SOLSTICE ongoing
Fundingindustry (company press release on own pipeline)
Comparatorsplacebo